Targeting the XIAP/caspase-7 complex selectively kills caspase-3-deficient malignancies

Yuan-Feng Lin, Tsung Ching Lai, Chih Kang Chang, Chi Long Chen, Ming Shyan Huang, Chih Jen Yang, Hon Ge Liu, Jhih Jhong Dong, Yi An Chou, Kuo Hsun Teng, Shih Hsun Chen, Wei Ting Tian, Yi Hua Jan, Michael Hsiao, Po Huang Liang

研究成果: 雜誌貢獻文章同行評審

19 引文 斯高帕斯(Scopus)


Caspase-3 downregulation (CASP3/DR) in tumors frequently confers resistance to cancer therapy and is significantly correlated with a poor prognosis in cancer patients. Because CASP3/DR cancer cells rely heavily on the activity of caspase-7 (CASP7) to initiate apoptosis, inhibition of activated CASP7 (p19/p12-CASP7) by X-linked inhibitor of apoptosis protein (XIAP) is a potential mechanism by which apoptosis is prevented in those cancer cells. Here, we identify the pocket surrounding the Cys246 residue of p19/p12-CASP7 as a target for the development of a protein-protein interaction (PPI) inhibitor of the XIAP:p19/p12-CASP7 complex. Interrupting this PPI directly triggered CASP7-dependent apoptotic signaling that bypassed the activation of the apical caspases and selectively killed CASP3/DR malignancies in vitro and in vivo without adverse side effects in nontumor cells. Importantly, CASP3/DR combined with p19/p12-CASP7 accumulation correlated with the aggressive evolution of clinical malignancies and a poor prognosis in cancer patients. Moreover, targeting of this PPI effectively killed cancer cells with multidrug resistance due to microRNA let-7a-1-mediated CASP3/DR and resensitized cancer cells to chemotherapy-induced apoptosis. These findings not only provide an opportunity to treat CASP3/DR malignancies by targeting the XIAP:p19/p12-CASP7 complex, but also elucidate the molecular mechanism underlying CASP3/DR in cancers.

頁(從 - 到)3861-3875
期刊Journal of Clinical Investigation
出版狀態已發佈 - 9月 3 2013

ASJC Scopus subject areas

  • 醫藥 (全部)


深入研究「Targeting the XIAP/caspase-7 complex selectively kills caspase-3-deficient malignancies」主題。共同形成了獨特的指紋。